Success Stories: Advancing Therapeutics in Ophthalmology: EB1A Approved for a Leading Physician-Scientist

Client’s Testimonial:

“I truly appreciate all the hard work and dedication that you put into my case. It has been a great experience working with you, and I’m very grateful for your guidance throughout the process.”

On May 20^th, 2025, we received another EB-1A (Alien of Extraordinary Ability) approval for an Ophthalmology Researcher (Approval Notice).

General Field: Ophthalmology

Country of Origin: Iran

Country of Residence at the Time of Filing: Iran

Approval Notice Date: May 20^th, 2025

Processing Time: 20 days (Premium Processing Requested)

Case Summary:

We are pleased to announce the successful EB1A (Alien of Extraordinary Ability) approval of a distinguished medical researcher from Iran, whose pioneering work in ophthalmology has yielded significant contributions to the diagnosis and treatment of ocular surface disorders. This approval, granted on May 20, 2025, reflects the petitioner’s exceptional qualifications and the sustained international impact of his research.

A Global Leader in Ocular Surface Research

With a focus on ocular surface disorders, regenerative medicine, and clinical ophthalmology, the petitioner has established himself as a foremost expert in the field. His scholarly work is particularly known for advancing treatment protocols for corneal infections and developing novel bioscaffolds for tissue engineering applications.

Currently engaged in clinical research, he has received a letter of intent from a leading U.S. medical institution to continue his work on advanced diagnostic techniques and stem cell therapy for ocular diseases.

An Extensive Record of Scholarly Achievement

The petitioner has authored 47 peer-reviewed publications. His research has been cited over 815 times, and at least nine of his articles are among the top 10% or 1% most-cited in clinical medicine for their respective publication years.

He has also completed at least 60 peer reviews for prominent ophthalmology journals. His role as a reviewer for these selective journals further attests to his standing within the field.

Scientific Contributions with Lasting Global Impact

The petitioner has made significant contributions across multiple domains within ophthalmology, including clinical practice, regenerative medicine, and public health. His work has supported advancements in diagnostics, treatment strategies, and biomedical innovation. Collectively, his findings have been cited by scholars in at least 56 countries, and researchers from institutions in China, the UAE, Germany, and the United States have incorporated his methodologies and data into their own high-impact publications.

As one expert recommender noted:

“His work offers critical insights into therapeutic approaches for corneal infections that have global relevance and are actively shaping clinical guidelines.”

Conclusion

Through rigorous peer-reviewed scholarship, international collaboration, and high-profile recognition, this petitioner has demonstrated the hallmarks of extraordinary ability in ophthalmology. His research is not only improving outcomes for patients with complex ocular diseases but also strengthening the scientific foundation upon which future therapies are built.

We are proud to support individuals of such outstanding merit, and we look forward to seeing the continued impact of his work in the United States and beyond.

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 58,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to over 58,000 in 2025.